Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

Y0000401

Pimobendan for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Pimobendan, 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H18N4O2
CAS Number:
Molecular Weight:
334.37
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

pimobendan

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C(C1=CC=C(NC(C2=CC=C(OC)C=C2)=N3)C3=C1)=NN4)CC4=O

InChI

1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)

InChI key

GLBJJMFZWDBELO-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Pimobendan for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Suzuki et al.
Journal of veterinary internal medicine, 25(6), 1328-1333 (2011-11-19)
The effects of pimobendan on left atrial pressure (LAP) in dogs with mitral valve disease (MR) have not been documented in a quantitative manner. The objective was to document and study the short-term effects of pimobendan on LAP and echocardiographic
John M Macgregor et al.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 13(4), 251-260 (2011-10-28)
To describe the therapeutic use of pimobendan in cats, describe the patient population to which it was administered, document potential side effects and report the clinical course following administration of pimobendan in conjunction with standard heart failure therapy. It is
L Noelani Reinker et al.
Journal of the American Animal Hospital Association, 48(4), 250-255 (2012-05-23)
The purpose of this study was to review the medical records of dogs that were either suspected or known to have ingested large doses of pimobendan and to describe the clinical signs associated with pimobendan toxicosis. The database of Pet
K J Atkinson et al.
Journal of veterinary internal medicine, 23(6), 1190-1196 (2009-09-29)
Pimobendan is a positive inotrope and vasodilator that may be useful in the treatment of pulmonary hypertension (PHT) secondary to degenerative mitral valve disease. Pimobendan decreases the severity of PHT measured echocardiographically and improves quality-of-life scores. Changes in N-terminal probrain
Adrian Boswood
The Veterinary clinics of North America. Small animal practice, 40(4), 571-580 (2010-07-09)
Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs. The best evidence regarding its efficacy is derived from several clinical studies of dogs with the two most

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service